CN1802170A - 利用IFN－β治疗慢性炎性脱髓鞘性多神经病 - Google Patents

利用IFN－β治疗慢性炎性脱髓鞘性多神经病 Download PDF

Info

Publication number
CN1802170A
CN1802170A CNA038253720A CN03825372A CN1802170A CN 1802170 A CN1802170 A CN 1802170A CN A038253720 A CNA038253720 A CN A038253720A CN 03825372 A CN03825372 A CN 03825372A CN 1802170 A CN1802170 A CN 1802170A
Authority
CN
China
Prior art keywords
ifn
beta
cidp
therapeutic agent
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038253720A
Other languages
English (en)
Chinese (zh)
Inventor
艾尔弗雷德·桑德罗克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN1802170A publication Critical patent/CN1802170A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA038253720A 2002-09-27 2003-09-26 利用IFN－β治疗慢性炎性脱髓鞘性多神经病 Pending CN1802170A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
US60/414,307 2002-09-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010256064XA Division CN102038938A (zh) 2002-09-27 2003-09-26 利用IFN-β治疗慢性炎性脱髓鞘性多神经病

Publications (1)

Publication Number Publication Date
CN1802170A true CN1802170A (zh) 2006-07-12

Family

ID=32043377

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038253720A Pending CN1802170A (zh) 2002-09-27 2003-09-26 利用IFN－β治疗慢性炎性脱髓鞘性多神经病
CN201010256064XA Pending CN102038938A (zh) 2002-09-27 2003-09-26 利用IFN-β治疗慢性炎性脱髓鞘性多神经病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010256064XA Pending CN102038938A (zh) 2002-09-27 2003-09-26 利用IFN-β治疗慢性炎性脱髓鞘性多神经病

Country Status (21)

Country Link
US (2) US20060182715A1 (enExample)
EP (1) EP1575531B9 (enExample)
JP (3) JP2006513990A (enExample)
KR (1) KR20050059195A (enExample)
CN (2) CN1802170A (enExample)
AT (1) ATE520412T1 (enExample)
AU (1) AU2003277006C1 (enExample)
BR (1) BR0314548A (enExample)
CA (1) CA2500189A1 (enExample)
DK (1) DK1575531T3 (enExample)
EA (1) EA009289B1 (enExample)
GE (1) GEP20094699B (enExample)
IS (1) IS7746A (enExample)
MX (1) MXPA05003243A (enExample)
NO (1) NO20052059L (enExample)
NZ (1) NZ565990A (enExample)
PL (1) PL377612A1 (enExample)
RS (1) RS20050255A (enExample)
UA (1) UA86749C2 (enExample)
WO (1) WO2004028472A2 (enExample)
ZA (1) ZA200502416B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20094699B (en) * 2002-09-27 2009-06-10 Biogen Idec Inc THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
CN109134642A (zh) * 2011-10-01 2019-01-04 株式会社糖锁工学研究所 加成糖链的多肽及含有该多肽的医药组合物
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520760D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Encoding methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) * 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
EA004789B9 (ru) * 1998-10-16 2017-05-31 Байоджен, Инк. Полимерные конъюгаты бета-1а-интерферона и их использование
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
JP2002537769A (ja) * 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
GEP20094699B (en) * 2002-09-27 2009-06-10 Biogen Idec Inc THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON

Also Published As

Publication number Publication date
IS7746A (is) 2005-03-15
EA009289B1 (ru) 2007-12-28
GEP20094699B (en) 2009-06-10
NO20052059L (no) 2005-06-27
NO20052059D0 (no) 2005-04-27
EP1575531A2 (en) 2005-09-21
JP2006513990A (ja) 2006-04-27
RS20050255A (sr) 2007-08-03
EP1575531A4 (en) 2008-01-23
CA2500189A1 (en) 2004-04-08
ATE520412T1 (de) 2011-09-15
WO2004028472A3 (en) 2006-01-19
AU2003277006B2 (en) 2009-09-10
AU2003277006A1 (en) 2004-04-19
US20120058083A1 (en) 2012-03-08
UA86749C2 (en) 2009-05-25
EA200500545A2 (ru) 2005-08-25
US20060182715A1 (en) 2006-08-17
MXPA05003243A (es) 2005-09-12
BR0314548A (pt) 2005-08-09
PL377612A1 (pl) 2006-02-06
DK1575531T3 (da) 2011-11-21
WO2004028472A2 (en) 2004-04-08
EP1575531B9 (en) 2012-02-22
JP2011132248A (ja) 2011-07-07
AU2003277006C1 (en) 2010-04-01
ZA200502416B (en) 2005-10-20
CN102038938A (zh) 2011-05-04
KR20050059195A (ko) 2005-06-17
NZ565990A (en) 2009-10-30
JP2007039463A (ja) 2007-02-15
EP1575531B1 (en) 2011-08-17
EA200500545A3 (ru) 2007-04-27

Similar Documents

Publication Publication Date Title
CN1681527A (zh) 使用干扰素－β治疗肾衰竭
CN1333785A (zh) 干扰素－β融合蛋白及用途
CN1323225A (zh) 干扰素－β－1α的聚合物缀合物及其使用
CN1283659C (zh) 截短的神经胶质细胞系来源的神经营养因子
US20120058083A1 (en) Therapies for Chronic Inflammatory Demyelinating Polyneuropathy Using Interferon-Beta
CN1602201A (zh) 具有血小板生成活性的肽和相关的化合物
HK1046694A1 (zh) 干扰素-α蛋白作为FC融合蛋白的表达和运输
CN1902222A (zh) 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
CN1433324A (zh) 干扰素γ偶联物
CN1182453A (zh) Mpl配体类似物
JP2006513990A5 (enExample)
CN1852732A (zh) 具有增强的生物学效用的干扰素－β的聚合物缀合物
CN1187447C (zh) Mpl配体类似物
CN1822852A (zh) 改良的重组人干扰素－β－1b多肽
CN1694718A (zh) 修饰的无唾液酸－干扰素及其用途
CN1180312A (zh) 抗肥胖蛋白
HK1024490B (en) Pharmaceutical compositions containing an mpl ligand
HK1024490A1 (en) Pharmaceutical compositions containing an mpl ligand
HK1141998A (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
HK1031397B (en) Mpl ligand analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060712